Tsigkas, Grigorios
Apostolos, Anastasios
Trigka, Aikaterini
Chlorogiannis, Dimitrios
Katsanos, Konstantinos
Toutouzas, Konstantinos
Alexopoulos, Dimitrios
Brilakis, Emmanouil S.
Davlouros, Periklis
Funding for this research was provided by:
University of Patras
Article History
Accepted: 1 November 2022
First Online: 20 December 2022
Declarations
:
: No sources of funding were used to assist in the preparation of this articles.
: Grigorios Tsigkas has received advisory board/lecturing fees from Astra Zeneca, Menarini, Pfizer, and Boehringer Ingelheim. Konstantinos Toutouzas has received honorarium from Sanofi Adventist. Dimitrios Alexopoulos has received advisory board/lecturing fees from Astra Zeneca, Bayer, Pfizer, Boehringer Ingelheim, Medtronic, Biotronik, and Chiesi Hellas. Emmanouil S. Brilakis has received consulting/speaker honoraria from Abbott Vascular, American Heart Association (Associate Editor Circulation), Amgen, Asahi Intecc, Biotronik, Boston Scientific, Cardiovascular Innovations Foundation (Board of Directors), ControlRad, CSI, Elsevier, GE Healthcare, IMDS, InfraRedx, Medicure, Medtronic, Opsens, Siemens, and Teleflex; and research support from Boston Scientific, GE Healthcare. He is also an owner of Hippocrates LLC; and a shareholder of MHI Ventures, Cleerly Health, and Stallion Medical. Periklis Davlouros has received advisory board/lecturing fees from Astra Zeneca, Bayer, Menarini, Pfizer, and Boehringer Ingelheim. Anastasios Apostolos, Aikaterini Trigka, Dimitrios Chlorogiannis, and Konstantinos Katsanos declare no conflicts of interest.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: GT, AA, and PD designed the analysis. AA, AT, and DC collected the data. AA and KK performed the analysis. GT and AA wrote the manuscript. KT, DA, ESB, and PD reviewed the manuscript. All authors approved the final manuscript.